Editorials

Aspirin resistance in cardiovascular disease

BMJ 2008; 336 doi: https://doi.org/10.1136/bmj.39405.635498.80 (Published 24 January 2008) Cite this as: BMJ 2008;336:166
  1. Giuseppe Biondi-Zoccai, assistant professor in cardiology1,
  2. Marzia Lotrionte, consultant cardiologist2
  1. 1Division of Cardiology, University of Turin, 10126 Turin, Italy
  2. 2Institute of Cardiology, Catholic University, 00136 Rome, Italy
  1. gbiondizoccai{at}gmail.com

    Carries a worse prognosis, but may be indicative of pre-existing higher risk

    Aspirin has clear benefits in cardiovascular disease. It reduces total mortality, cardiovascular mortality, and cardiovascular morbidity in people with cardiovascular disease or those at high risk of the disease; it is also cheap, relatively safe, and easy to use.1 So why does aspirin fail to work in some people who take it as prescribed? Research on this clinical “resistance” to aspirin has tried to assess whether the effect on the in vitro activation of platelets depends only on the dose and type of antithrombotic agent given, or whether some people respond poorly (“resist”) to a specific drug, as some people do to specific antibiotics. In the accompanying systematic review, Krasopoulos and colleagues assess whether resistance to aspirin is related to cardiovascular outcomes in people with cardiovascular disease.2

    To date, most research has focused on whether aspirin resistance …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe